- Home
- DCOY vs INDP Comparison
DCOY vs INDP Comparison
Compare DCOY & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DCOY | INDP |
|---|---|---|
| Founded | N/A | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7M | 4.5M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | DCOY | INDP |
|---|---|---|
| Price | $7.70 | $1.75 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $30.00 | N/A |
| AVG Volume (30 Days) | ★ 67.4K | 19.2K |
| Earning Date | 03-23-2026 | 03-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.53 | $0.27 |
| 52 Week High | $9.09 | $13.24 |
Technical Indicators
Market Signals| Indicator | DCOY | INDP |
|---|---|---|
| Relative Strength Index (RSI) | 73.72 | 39.06 |
| Support Level | $0.61 | $0.27 |
| Resistance Level | $8.74 | $2.18 |
| Average True Range (ATR) | 0.43 | 0.15 |
| MACD | 0.31 | -0.00 |
| Stochastic Oscillator | 78.50 | 5.06 |
Price Performance
Historical ComparisonAbout DCOY Decoy Therapeutics Inc. Common Stock
Decoy Therapeutics Inc is a preclinical-stage biotechnology company developing peptide conjugate drug candidates using machine learning, artificial intelligence tools, and high-throughput synthesis techniques. The company's initial pipeline is focused on respiratory viruses and GI cancers.
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.